Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: A prospective, two-stage study.
The Lancet Oncology.
Times cited: 78
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Journal of Clinical Oncology.
Times cited: 344